MARKET

CGTX

CGTX

COGNITION THERAPEUTICS INC
NASDAQ
1.060
+0.060
+6.03%
After Hours: 1.070 +0.01 +0.94% 19:56 02/06 EST
OPEN
1.000
PREV CLOSE
0.9997
HIGH
1.080
LOW
0.9998
VOLUME
973.72K
TURNOVER
--
52 WEEK HIGH
3.830
52 WEEK LOW
0.2223
MARKET CAP
93.57M
P/E (TTM)
-2.2010
1D
5D
1M
3M
1Y
5Y
1D
BUZZ-U.S. STOCKS ON THE MOVE-Netflix, FirstCash Holdings, CF Bankshares
Reuters · 3d ago
BUZZ-U.S. STOCKS ON THE MOVE-OneSpaWorld, IMUNON, Cigna 
Reuters · 3d ago
BUZZ-Cognition Therapeutics rises as it extends access to rare brain disorder drug
Reuters · 3d ago
Cognition Therapeutics Extends Duration Of Expanded Access Program For Dementia With Lewy Bodies
Benzinga · 3d ago
COGNITION THERAPEUTICS EXTENDS EXPANDED ACCESS PROGRAM FOR ZERVIMESINE (CT1812) IN DEMENTIA WITH LEWY BODIES
Reuters · 3d ago
Weekly Report: what happened at CGTX last week (0126-0130)?
Weekly Report · 6d ago
Cognition Therapeutics Advances Zervimesine Toward Phase 2b Trial
TipRanks · 01/27 12:57
Cognition Therapeutics Meets With FDA to Plan Mid-Stage Trial for Lewy Body Dementia Drug
Benzinga · 01/27 12:37
More
About CGTX
Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of small molecule therapeutics targeting age-related degenerative disorders of the central nervous system and retina. The Company is investigating its lead candidate, zervimesine (CT1812), in clinical programs in dementia with Lewy bodies (DLB) and Alzheimer’s disease. Its CT1812 and pipeline of sigma-2 modulators can regulate pathways that are impaired in these diseases for the treatment of degenerative diseases. Its lead product candidate, CT1812, is an orally delivered, small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins. Its pipeline candidates were discovered using proprietary biology and chemistry platforms designed to identify novel drug targets and disease-modifying therapies that address dysregulated pathways. It is developing other product candidates in the area of synucleinopathies.

Webull offers Cognition Therapeutics Inc stock information, including NASDAQ: CGTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CGTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CGTX stock methods without spending real money on the virtual paper trading platform.